THE ARISING · Longevity & Healthspan
Humacyte Begins First Human Trial of Lab-Grown Coronary Bypass Vessel
Humacyte has opened enrollment for a first human study of a lab-grown coronary bypass vessel. Human safety and efficacy results are not yet available.
According to Humacyte's November 9 announcement, Humacyte has opened enrollment in a Phase 2a clinical study of its investigational coronary tissue-engineered vessel, known as CTEV. The study involves patients undergoing coronary artery bypass grafting, a surgery that reroutes blood around blocked heart arteries.
The report says the FDA accepted Humacyte's investigational new drug application in July 2026. The trial will evaluate the safety and efficacy of the CTEV as a vascular conduit, meaning a channel that carries blood, in ten adult patients. Patency, a measure of whether the graft stays open, will be assessed at two months. Follow-up will run for up to three years.
The company describes the CTEV as an off-the-shelf, small-diameter conduit designed to be repopulated by a patient's own cells. According to the report, it is made with the same manufacturing system as Humacyte's FDA-approved acellular tissue-engineered vessel.
The CTEV and Humacyte's regenerative platform were highlighted at the American Heart Association Scientific Sessions 2026 in Chicago. Presentations covered the Phase 2a study design and engineering approaches meant to speed vascular regeneration, according to the report.
Animal data were also presented. In sheep, CTEV bypasses of about 12 centimeters were implanted for up to three months, and the report says they stayed open and were populated by the host's own cells. Porcine data were also part of the preclinical work. These are animal findings, and the ten-patient trial is the first test in people.
The CTEV remains investigational and has not been approved for sale by the FDA. Next to watch: the two-month patency results from the ten patients, and the longer follow-up that extends to three years.